SEC Comment Letter 0000000000-24-000002 to Deciphera Pharmaceuticals, Inc. (CIK 0001654151)
Deciphera Pharmaceuticals, Inc. (CIK 0001654151)
Date: Jan. 2, 2024 · CIK: 0001654151 · Accession: 0000000000-24-000002
AI Filing Summary & Sentiment
File numbers found in text: 001-38219
Letter
United States securities and exchange commission logo January 2, 2024 Thomas P. Kelly Chief Financial Officer Deciphera Pharmaceuticals, Inc. 200 Smith Street Waltham, MA 02451 Re:Deciphera Pharmaceuticals, Inc. Form 10-K for the Year Ended December 31, 2022 Filed February 7, 2023 File No. 001-38219 Dear Thomas P. Kelly: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
January 2, 2024
Thomas P. Kelly
Chief Financial Officer
Deciphera Pharmaceuticals, Inc.
200 Smith Street
Waltham, MA 02451
Re:Deciphera Pharmaceuticals, Inc.
Form 10-K for the Year Ended December 31, 2022
Filed February 7, 2023
File No. 001-38219
Dear Thomas P. Kelly:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences